Literature DB >> 10948122

Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.

Z Kossaczka1, J Shiloach, V Johnson, D N Taylor, R A Finkelstein, J B Robbins, S C Szu.   

Abstract

Epidemiologic and experimental data provide evidence that a critical level of serum immunoglobulin G (IgG) antibodies to the surface polysaccharide of Vibrio cholerae O1 (lipopolysaccharide) and of Vibrio cholerae O139 (capsular polysaccharide [CPS]) is associated with immunity to the homologous pathogen. The immunogenicity of polysaccharides, especially in infants, may be enhanced by their covalent attachment to proteins (conjugates). Two synthetic schemes, involving 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) as activating agents, were adapted to prepare four conjugates of V. cholerae O139 CPS with the recombinant diphtheria toxin mutant, CRMH21G. Adipic acid dihydrazide was used as a linker. When injected subcutaneously into young outbred mice by a clinically relevant dose and schedule, these conjugates elicited serum CPS antibodies of the IgG and IgM classes with vibriocidal activity to strains of capsulated V. cholerae O139. Treatment of these sera with 2-mercaptoethanol (2-ME) reduced, but did not eliminate, their vibriocidal activity. These results indicate that the conjugates elicited IgG with vibriocidal activity. Conjugates also elicited high levels of serum diphtheria toxin IgG. Convalescent sera from 20 cholera patients infected with V. cholerae O139 had vibriocidal titers ranging from 100 to 3,200: absorption with the CPS reduced the vibriocidal titer of all sera to < or =50. Treatment with 2-ME reduced the titers of 17 of 20 patients to < or =50. These data show that, like infection with V. cholerae O1, infection with V. cholerae O139 induces vibriocidal antibodies specific to the surface polysaccharide of this bacterium (CPS) that are mostly of IgM class. Based on these data, clinical trials with the V. cholerae O139 CPS conjugates with recombinant diphtheria toxin are planned.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948122      PMCID: PMC101731          DOI: 10.1128/IAI.68.9.5037-5043.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents.

Authors:  A Lees; B L Nelson; J J Mond
Journal:  Vaccine       Date:  1996-02       Impact factor: 3.641

2.  The immunological responses observed in field studies in Africa with group A meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; J Etienne; W R Sanborn; R Triau; B Cvjetanović
Journal:  Prog Immunobiol Stand       Date:  1971

3.  Kinetics of the vibriocidal antibody response to live oral cholera vaccines.

Authors:  S S Wasserman; G A Losonsky; F Noriega; C O Tacket; E Castañeda; M M Levine
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

4.  Colonial opacity variations among the choleragenic vibrios.

Authors:  Richard A Finkelstein; Mary Boesman-Finkelstein; Dilip K Sengupta; William J Page; C Michael Stanley; Thomas E Phillips
Journal:  Microbiology (Reading)       Date:  1997-01       Impact factor: 2.777

5.  Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.

Authors:  J G Morris; G E Losonsky; J A Johnson; C O Tacket; J P Nataro; P Panigrahi; M M Levin
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

6.  Histidine 21 does not play a major role in diphtheria toxin catalysis.

Authors:  V G Johnson; P J Nicholls
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

7.  Structure of the capsular polysaccharide of Vibrio cholerae O139 synonym Bengal containing D-galactose 4,6-cyclophosphate.

Authors:  Y A Knirel; L Paredes; P E Jansson; A Weintraub; G Widmalm; M J Albert
Journal:  Eur J Biochem       Date:  1995-09-01

8.  The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants.

Authors:  M K Waldor; R Colwell; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

9.  Morphological and physical characterization of the capsular layer of Vibrio cholerae O139.

Authors:  Y Meno; M K Waldor; J J Mekalanos; K Amako
Journal:  Arch Microbiol       Date:  1998-10       Impact factor: 2.552

10.  Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.

Authors:  A S Benenson; A Saad; W H Mosley
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

View more
  16 in total

Review 1.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

2.  Evaluation of synthetic schemes to prepare immunogenic conjugates of Vibrio cholerae O139 capsular polysaccharide with chicken serum albumin.

Authors:  Z Kossaczka; S C Szu
Journal:  Glycoconj J       Date:  2000-06       Impact factor: 2.916

3.  Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid.

Authors:  A Boutonnier; S Villeneuve; F Nato; B Dassy; J M Fournier
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Authors:  Russell A Johnson; Taher Uddin; Amena Aktar; M Mohasin; Mohammad Murshid Alam; Fahima Chowdhury; Jason B Harris; Regina C LaRocque; Meagan Kelly Bufano; Yanan Yu; Ying Wu-Freeman; Daniel T Leung; David Sarracino; Bryan Krastins; Richelle C Charles; Peng Xu; Pavol Kovác; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

Review 5.  Vibrio cholerae: lessons for mucosal vaccine design.

Authors:  Anne L Bishop; Andrew Camilli
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

6.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

7.  Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice.

Authors:  Stefan Schild; Eric J Nelson; Andrew Camilli
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

8.  Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.

Authors:  Deborah R Leitner; Sandra Feichter; Kristina Schild-Prüfert; Gerald N Rechberger; Joachim Reidl; Stefan Schild
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

9.  Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.

Authors:  Cyrille Grandjean; Alain Boutonnier; Bruno Dassy; Jean-Michel Fournier; Laurence A Mulard
Journal:  Glycoconj J       Date:  2008-07-23       Impact factor: 2.916

10.  Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Taher Uddin; Peng Xu; Amena Aktar; Russell A Johnson; Mohammad Arif Rahman; Mohammad Murshid Alam; Meagan Kelly Bufano; Grace Eckhoff; Ying Wu-Freeman; Yanan Yu; Tania Sultana; Farhana Khanam; Amit Saha; Fahima Chowdhury; Ashraf I Khan; Richelle C Charles; Regina C Larocque; Jason B Harris; Stephen B Calderwood; Pavol Kovác; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2013-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.